Abstract
Yellow fever virus (YFV) causes a viral hemorrhagic fever, a systemic illness characterized by high viremia, hepatic, renal, and myocardial injury; hemorrhage; and high lethality. A highly effective vaccine (17D), developed in 1936, is widely used to protect travelers to and residents of endemic regions of tropical South America and sub-Saharan Africa. Although the vaccine provides long-lasting immunity, rare but serious side effects have emphasized the importance of determining the need for vaccination on a case-by-case basis and of continued exploration for next generation vaccines. This chapter provides background information on the basic virology, virus transmission, clinical disease presentation, pathogenesis, immune response, and epidemiology of YF before presenting detailed information on the development, immunogenicity, and reactogenicity of existing YFV vaccines. Finally, ongoing work to develop second generation vaccines, including inactivated vaccines, and alternative delivery routes for dose sparing are discussed.
Original language | English (US) |
---|---|
Title of host publication | Plotkin's Vaccines, Eighth Edition |
Publisher | Elsevier |
Pages | 1251-1321.e19 |
ISBN (Electronic) | 9780323790581 |
ISBN (Print) | 9780323790604 |
DOIs | |
State | Published - Jan 1 2023 |
Externally published | Yes |
Keywords
- adverse effect
- Non-MeSH terms for consideration: viscerotropic disease, adverse event following immunization
- vector borne diseasesmosquito vector
- yellow fever vaccinearbovirus infections
- Yellow feveryellow fever virus
ASJC Scopus subject areas
- General Medicine